22.04
price down icon8.36%   -2.0099
after-market 시간 외 거래: 22.33 0.2899 +1.32%
loading

Ascentage Pharma Group International Adr 주식(AAPG)의 최신 뉴스

pulisher
Mar 16, 2026

Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend - TipRanks

Mar 16, 2026
pulisher
Mar 12, 2026

Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update - The Globe and Mail

Mar 12, 2026
pulisher
Mar 11, 2026

Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 - GlobeNewswire Inc.

Mar 11, 2026
pulisher
Mar 11, 2026

Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 - Sahm

Mar 11, 2026
pulisher
Mar 10, 2026

Short Interest in Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Increases By 512.5% - MarketBeat

Mar 10, 2026
pulisher
Mar 05, 2026

Ascentage Pharma Group InternationalUnsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 05, 2026
pulisher
Mar 03, 2026

Ascentage Pharma Group International (NASDAQ:AAPG) Sees Large Volume IncreaseHere's What Happened - MarketBeat

Mar 03, 2026
pulisher
Mar 02, 2026

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap DownWhat's Next? - MarketBeat

Mar 02, 2026
pulisher
Feb 24, 2026

Analysts Are Bullish on Top Healthcare Stocks: Abivax SA Sponsored ADR (ABVX), Irhythm Technologies (IRTC) - The Globe and Mail

Feb 24, 2026
pulisher
Feb 23, 2026

Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences - TipRanks

Feb 23, 2026
pulisher
Feb 13, 2026

Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap UpStill a Buy? - MarketBeat

Feb 13, 2026
pulisher
Feb 11, 2026

Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target - Finviz

Feb 11, 2026
pulisher
Feb 09, 2026

Ascentage Pharma to Present at Guggenheim Biotech Summit as Late-Stage Oncology Pipeline Expands - TipRanks

Feb 09, 2026
pulisher
Feb 06, 2026

Ascentage Pharma Wins China IND Clearance for Next-Gen BTK Degrader APG-3288 - TipRanks

Feb 06, 2026
pulisher
Feb 05, 2026

Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 - Sahm

Feb 05, 2026
pulisher
Jan 31, 2026

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail

Jan 31, 2026
pulisher
Jan 30, 2026

Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail

Jan 30, 2026
pulisher
Jan 30, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Sees Significant Increase in Short Interest - Defense World

Jan 30, 2026
pulisher
Jan 17, 2026

Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) - The Globe and Mail

Jan 17, 2026
pulisher
Jan 17, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update - Defense World

Jan 17, 2026
pulisher
Jan 15, 2026

Ascentage Pharma Details 2026 Global Innovation Strategy at J.P. Morgan Healthcare Conference - TipRanks

Jan 15, 2026
pulisher
Jan 14, 2026

Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference - markets.businessinsider.com

Jan 14, 2026
pulisher
Jan 14, 2026

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Given Consensus Recommendation of “Buy” by Brokerages - Defense World

Jan 14, 2026
pulisher
Jan 14, 2026

Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Regeneron (REGN) and Progyny (PGNY) - The Globe and Mail

Jan 14, 2026
pulisher
Jan 09, 2026

LENZ Therapeutics (LENZ) Receives a Buy from Piper Sandler - The Globe and Mail

Jan 09, 2026
pulisher
Jan 08, 2026

Analysts Offer Insights on Healthcare Companies: BeOne Medicines (ONC) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jan 08, 2026
pulisher
Jan 07, 2026

Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial - TipRanks

Jan 07, 2026
pulisher
Jan 06, 2026

Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 - Sahm

Jan 06, 2026
pulisher
Dec 23, 2025

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Receives $48.50 Average Price Target from Brokerages - Defense World

Dec 23, 2025
pulisher
Dec 22, 2025

Ascentage Pharma Group International (NASDAQ:AAPG) Stock Price Down 5.5%Should You Sell? - MarketBeat

Dec 22, 2025
pulisher
Dec 17, 2025

Ascentage Pharma to Present at J.P. Morgan Healthcare Conference - TipRanks

Dec 17, 2025
pulisher
Dec 16, 2025

Ascentage Pharma to Engage Investors at December 2025 Conferences - MSN

Dec 16, 2025
$99.29
price up icon 1.20%
$27.80
price up icon 0.00%
$52.37
price down icon 0.06%
$89.31
price down icon 0.77%
$144.00
price up icon 0.91%
biotechnology ONC
$282.72
price up icon 0.15%
자본화:     |  볼륨(24시간):